Martin Calderon, L. & Pope, J. E. Scleroderma epidemiology update. Curr. Opin. Rheumatol. 33, 122–127 (2021).

Article  Google Scholar 

LeRoy, E. C. et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 15, 202–205 (1988).

CAS  PubMed  Google Scholar 

Hunzelmann, N. et al. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology 47, 1185–1192 (2008).

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Almeida Chaves, S. et al. Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality. Arthritis Res. Ther. 23, 295 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Marangoni, R. G. et al. Systemic sclerosis sine scleroderma: distinct features in a large Brazilian cohort. Rheumatology 52, 1520–1524 (2013).

Article  PubMed  Google Scholar 

Koenig, M. et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 58, 3902–3912 (2008).

Article  PubMed  Google Scholar 

Bellando-Randone, S. et al. Progression of patients with Raynaud’s phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for very early diagnosis of systemic sclerosis (VEDOSS). Lancet Rheumatol. 3, e834–e843 (2021).

Article  CAS  Google Scholar 

Muangchan, C. et al. The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review. J. Rheumatol. 40, 1545–1556 (2013).

Article  PubMed  Google Scholar 

Akesson, A. & Wollheim, F. A. Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. Br. J. Rheumatol. 28, 281–286 (1989).

Article  CAS  PubMed  Google Scholar 

Thoua, N. M. et al. Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre. Rheumatology 49, 1770–1775 (2010).

Article  PubMed  Google Scholar 

Fretheim, H. et al. Multidimensional tracking of phenotypes and organ involvement in a complete nationwide systemic sclerosis cohort. Rheumatology 59, 2920–2929 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Steen, V. D. & Medsger, T. A. Jr Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 43, 2437–2444 (2000).

Article  CAS  PubMed  Google Scholar 

Bussone, G. & Mouthon, L. Interstitial lung disease in systemic sclerosis. Autoimmun. Rev. 10, 248–255 (2011).

Article  PubMed  Google Scholar 

Pope, J. E. et al. Systemic sclerosis and associated interstitial lung disease in Ontario, Canada: an examination of prevalence and survival over 10 years. J. Rheumatol. 48, 1427–1434 (2021).

Article  PubMed  Google Scholar 

Fernandez-Codina, A. et al. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 70, 1820–1828 (2018).

Article  CAS  PubMed  Google Scholar 

Khanna, D. et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J. Scleroderma Relat. Disord. 2, 11–18 (2017).

Article  PubMed  Google Scholar 

Herrick, A. L. et al. Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Ann. Rheum. Dis. 77, 563–570 (2018).

Article  CAS  PubMed  Google Scholar 

Khanna, D. et al. The American College of Rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis. Arthritis Care Res. 68, 167–178 (2016).

Article  Google Scholar 

Spiera, R. et al. Safety and efficacy of lenabasum in a phase II, randomized, placebo-controlled trial in adults with systemic sclerosis. Arthritis Rheumatol. 72, 1350–1360 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chung, L. et al. Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. Lancet Rheumatol. 2, e743–e753 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Khanna, D. et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387, 2630–2640 (2016).

Article  CAS  PubMed  Google Scholar 

Khanna, D. et al. Evaluation of American college of rheumatology provisional composite response index in systemic sclerosis (ACR CRISS) in a phase 3 randomized controlled trial [abstract]. Arthritis Rheumatol. 70, 2938 (2018).

Google Scholar 

Nevskaya, T. et al. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. Rheumatology 59, 1715–1724 (2020).

Article  PubMed  Google Scholar 

Zheng, B. et al. Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity. Rheumatology 59, 398–406 (2020).

Article  PubMed  Google Scholar 

Burt, R. K. et al. Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days. Bone Marrow Transpl. 56, 50–59 (2021).

Article  CAS  Google Scholar 

Sullivan, K. M. et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N. Engl. J. Med. 378, 35–47 (2018).

Article  PubMed  PubMed Central  Google Scholar 

van Laar, J. M. et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311, 2490–2498 (2014).

Article  PubMed  Google Scholar 

Burt, R. K. et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 378, 498–506 (2011).

Article  CAS  PubMed  Google Scholar 

Shouval, R. et al. Autologous hematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis. Biol. Blood Marrow Transpl. 24, 937–944 (2018).

Article  Google Scholar 

Maltez, N. et al. Association of autologous hematopoietic stem cell transplantation in systemic sclerosis with marked improvement in health-related quality of life. Arthritis Rheumatol. 73, 305–314 (2021).

Article  PubMed  Google Scholar 

van Bijnen, S. et al. Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study. Ann. Rheum. Dis. 79, 1084–1089 (2020).

Article  PubMed  Google Scholar 

Guillaume-Jugnot, P. et al. Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French society for bone marrow transplantation and cellular therapy (SFGM-TC). Clin. Rheumatol. 38, 1501–1511 (2019).

Article  PubMed  Google Scholar 

Henes, J. et al. Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow transplantation autoimmune disease working party. Haematologica 106, 375–383 (2021).

Article  CAS  PubMed  Google Scholar 

Tashkin, D. P. et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 354, 2655–2666 (2006).

Article  CAS  PubMed  Google Scholar 

Tashkin, D. P. et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir. Med. 4, 708–719 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pope, J. E. et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 44, 1351–1358 (2001).

Article  CAS  PubMed  Google Scholar 

van den Hoogen, F. H. et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br. J. Rheumatol. 35, 364–372 (1996).

Article  PubMed  Google Scholar 

Gordon, J. K. et al. Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial. Arthritis Rheumatol. 70, 308–316 (2018).

Article  CAS  PubMed  Google Scholar 

Khanna, D. et al. Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial. Arthritis Rheumatol. 72, 125–136 (2020).

Article  CAS  PubMed